IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.377
EU - Europa 1.781
AS - Asia 1.377
SA - Sud America 487
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 6.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.327
SG - Singapore 583
BR - Brasile 440
IE - Irlanda 426
CN - Cina 359
SE - Svezia 355
IT - Italia 351
PL - Polonia 213
HK - Hong Kong 169
DE - Germania 98
VN - Vietnam 85
HU - Ungheria 61
RU - Federazione Russa 52
IN - India 39
FI - Finlandia 37
FR - Francia 37
GB - Regno Unito 37
ID - Indonesia 23
CA - Canada 22
BE - Belgio 21
MX - Messico 20
AT - Austria 18
NL - Olanda 16
ZA - Sudafrica 16
JP - Giappone 15
AR - Argentina 14
PK - Pakistan 14
TR - Turchia 13
ES - Italia 12
IQ - Iraq 12
UA - Ucraina 12
EG - Egitto 10
LT - Lituania 10
BD - Bangladesh 9
KR - Corea 8
MA - Marocco 8
AZ - Azerbaigian 7
EC - Ecuador 7
CZ - Repubblica Ceca 6
CL - Cile 5
PH - Filippine 5
TW - Taiwan 5
VE - Venezuela 5
JO - Giordania 4
KE - Kenya 4
PE - Perù 4
PS - Palestinian Territory 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
CO - Colombia 3
KG - Kirghizistan 3
NI - Nicaragua 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
UZ - Uzbekistan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BH - Bahrain 2
EU - Europa 2
NP - Nepal 2
PY - Paraguay 2
RS - Serbia 2
SA - Arabia Saudita 2
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GP - Guadalupe 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 6.073
Salva come PNG Salva come JPEG
Città #
Dublin 426
Chandler 384
Dallas 339
Ashburn 330
Singapore 284
Nyköping 228
Warsaw 210
Hong Kong 168
Messina 164
Beijing 139
Princeton 76
Los Angeles 71
Medford 64
Ann Arbor 63
Budapest 59
The Dalles 54
Munich 50
Des Moines 47
Jacksonville 42
New York 42
Dearborn 40
São Paulo 37
Buffalo 26
Dong Ket 25
Moscow 24
Brussels 21
Ho Chi Minh City 21
Redondo Beach 21
Tianjin 20
Rio de Janeiro 19
Boardman 18
Cambridge 18
Milan 18
Wilmington 18
Jakarta 17
Belo Horizonte 16
Hanoi 16
Jinan 16
Turku 16
Woodbridge 16
Nuremberg 15
Santa Clara 15
Brooklyn 14
Houston 13
Nanjing 13
Rome 13
Chennai 12
Hangzhou 12
Pune 12
Tokyo 12
Bremen 11
Vienna 11
Frankfurt am Main 10
Hebei 10
Montreal 10
Cairo 9
Johannesburg 9
Chicago 8
Ningbo 8
Palermo 8
Porto Alegre 8
San Francisco 8
San Mateo 8
Seattle 8
Zhengzhou 8
Baku 7
Boston 7
Brasília 7
Denver 7
London 7
Shenyang 7
Helsinki 6
Lahore 6
Osasco 6
Redwood City 6
Stockholm 6
Toronto 6
Belém 5
Bengaluru 5
Fortaleza 5
Fuzhou 5
Guarulhos 5
Haikou 5
Lanzhou 5
Mexico City 5
Poplar 5
Strasbourg 5
Amman 4
Cape Town 4
Casablanca 4
Curitiba 4
Falls Church 4
Latina 4
Londrina 4
Madrid 4
Olomouc 4
Palhoça 4
Paris 4
Ribeirão Preto 4
Shanghai 4
Totale 4.108
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 223
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 183
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 178
A multivariate analysis of Multiple Myeloma subtype plasma cells 177
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 155
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 143
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 140
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 136
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 130
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 128
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 125
The cancer stem cell hypothesis: a guide to potential molecular targets. 123
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 123
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 119
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 116
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 115
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 114
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 113
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 113
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 112
Vaccination of multiple myeloma: Current strategies and future prospects 112
Telomerase and telomere biology in hematological diseases: A new therapeutic target 111
Role of the microbiota in hematologic malignancies. 109
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 106
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 106
Vaccination strategies in lymphoproliferative disorders: Failures and successes 105
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 99
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules 98
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 94
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 94
The metabolomic signature of hematologic malignancies 91
Standardisation of minimal residual disease in multiple myeloma 90
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 89
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 88
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 85
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 83
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 83
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 79
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 78
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 78
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 77
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 76
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 74
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 72
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 70
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 69
Nanobodies and Cancer: Current Status and New Perspectives 68
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 66
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 66
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 66
Immune thrombocytopenia: options and new perspectives 66
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 65
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 62
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 61
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 59
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 59
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 58
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 56
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 55
New orally active proteasome inhibitors in multiple myeloma. 54
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 53
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 53
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 51
Relationship between mitofusin 2 and cancer. 49
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 45
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 37
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 35
null 19
Totale 6.285
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.029
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.029
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021321 0 0 0 0 0 29 48 38 61 89 14 42
2021/2022486 4 25 8 22 14 11 27 19 22 96 39 199
2022/20231.278 119 135 65 120 65 123 9 70 505 11 35 21
2023/2024335 22 75 28 26 29 62 2 20 1 17 7 46
2024/20251.557 83 32 21 89 91 73 36 243 402 96 173 218
2025/20261.606 231 284 373 249 409 60 0 0 0 0 0 0
Totale 6.285